AU2017310263B2 - Metabolites for treatment and prevention of autoimmune disease - Google Patents

Metabolites for treatment and prevention of autoimmune disease Download PDF

Info

Publication number
AU2017310263B2
AU2017310263B2 AU2017310263A AU2017310263A AU2017310263B2 AU 2017310263 B2 AU2017310263 B2 AU 2017310263B2 AU 2017310263 A AU2017310263 A AU 2017310263A AU 2017310263 A AU2017310263 A AU 2017310263A AU 2017310263 B2 AU2017310263 B2 AU 2017310263B2
Authority
AU
Australia
Prior art keywords
individual
short chain
chain fatty
fatty acids
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017310263A
Other languages
English (en)
Other versions
AU2017310263A1 (en
Inventor
Julie CLARKE
Trevor Lockett
Charles Reay Mackay
Eliana Marino MORENO
David Topping
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Monash University
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903143A external-priority patent/AU2016903143A0/en
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO, Monash University filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of AU2017310263A1 publication Critical patent/AU2017310263A1/en
Application granted granted Critical
Publication of AU2017310263B2 publication Critical patent/AU2017310263B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pediatric Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017310263A 2016-08-10 2017-08-10 Metabolites for treatment and prevention of autoimmune disease Active AU2017310263B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016903143A AU2016903143A0 (en) 2016-08-10 Metabolites for treatment of autoimmune disease
AU2016903143 2016-08-10
PCT/AU2017/050845 WO2018027274A1 (en) 2016-08-10 2017-08-10 Metabolites for treatment and prevention of autoimmune disease

Publications (2)

Publication Number Publication Date
AU2017310263A1 AU2017310263A1 (en) 2019-02-07
AU2017310263B2 true AU2017310263B2 (en) 2023-08-10

Family

ID=61160999

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017310263A Active AU2017310263B2 (en) 2016-08-10 2017-08-10 Metabolites for treatment and prevention of autoimmune disease

Country Status (8)

Country Link
US (3) US20190167615A1 (enExample)
EP (1) EP3496708B1 (enExample)
JP (1) JP7097027B2 (enExample)
CN (1) CN109562088A (enExample)
AU (1) AU2017310263B2 (enExample)
CA (1) CA3070939A1 (enExample)
ES (1) ES3029611T3 (enExample)
WO (1) WO2018027274A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
AU2019358875B2 (en) * 2018-10-09 2025-08-21 Monash University Combination therapy for treatment and prevention of autoimmune and inflammatory diseases
CN109771404A (zh) * 2019-02-28 2019-05-21 北京大学人民医院(北京大学第二临床医学院) 丁酸在制备预防和/或治疗自身免疫性疾病药物中的应用
EP3838283A1 (en) * 2019-12-18 2021-06-23 Mundus Sanus GmbH & Co. KG Composition for use in the treatment of provocative diseases
US20230190942A1 (en) * 2020-06-03 2023-06-22 Corn Products Development, Inc. Compositions of tri-substituted starch and methods for making and using the same
CN115068458B (zh) * 2022-07-21 2023-12-12 哈尔滨医科大学 戊酸在制备防治糖尿病药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066433A1 (en) * 2013-10-31 2015-05-07 Sloan-Kettering Institute For Cancer Research Methods and compositions for inducing regulatory t-cell generation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039703A (en) * 1989-11-16 1991-08-13 Breuer Richard I Method for treating inflammatory bowel disorders
US5840860A (en) 1993-11-17 1998-11-24 Commonwealth Scientific And Industrial Research Organization Fatty acid delivery system comprising a hydrolyzable bond
AUPQ132599A0 (en) 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
DE102005046237A1 (de) * 2005-09-28 2007-04-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
WO2014145970A1 (en) * 2013-03-15 2014-09-18 President And Fellows Of Harvard College Modulation of regulatory t cells via g-coupled protein receptor 43
US10226443B2 (en) * 2014-10-16 2019-03-12 New York University Methods for treating psoriatic arthritis
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US11065217B2 (en) * 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
AU2019358875B2 (en) * 2018-10-09 2025-08-21 Monash University Combination therapy for treatment and prevention of autoimmune and inflammatory diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066433A1 (en) * 2013-10-31 2015-05-07 Sloan-Kettering Institute For Cancer Research Methods and compositions for inducing regulatory t-cell generation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOPPING D.L. et al., MICROBIAL ECOLOGY IN HEALTH AND DISEASE, vol. 20, no. 2, 1 January 2008, pages 103 - 108 *

Also Published As

Publication number Publication date
JP2019527714A (ja) 2019-10-03
EP3496708C0 (en) 2025-03-26
AU2017310263A1 (en) 2019-02-07
WO2018027274A1 (en) 2018-02-15
ES3029611T3 (en) 2025-06-27
EP3496708A4 (en) 2020-04-01
CA3070939A1 (en) 2018-02-15
US20190167615A1 (en) 2019-06-06
US20210244692A1 (en) 2021-08-12
EP3496708B1 (en) 2025-03-26
JP7097027B2 (ja) 2022-07-07
EP3496708A1 (en) 2019-06-19
US20250295617A1 (en) 2025-09-25
CN109562088A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
US20250295617A1 (en) Metabolites for treatment and prevention of autoimmune disease
Gorkiewicz et al. Gut microbiome: a new player in gastrointestinal disease
DeGruttola et al. Current understanding of dysbiosis in disease in human and animal models
JP6944965B2 (ja) 大腸ガンのプロバイオティクスによる防止および処置
Jamwal et al. Intestinal epithelial expression of MHCII determines severity of chemical, T-cell–induced, and infectious colitis in mice
Kaser et al. The unfolded protein response and gastrointestinal disease
Janowitz et al. The role of the fecal stream in Crohn's disease: an historical and analytic review
Kim et al. Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice
US20160120915A1 (en) Methods for manipulating immune responses by altering microbiota
JP2009537547A (ja) 生物学的治療組成物およびその使用
Kabi et al. Digesting the genetics of inflammatory bowel disease: insights from studies of autophagy risk genes
JP2018532779A (ja) 糖尿病及び腸疾患の治療又は予防における使用のためのフィーカリバクテリウムプラウスニッツィ及びデスルホビブリオピゲル
FR2962045A1 (fr) Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
JP2021118687A (ja) 新規のビフィドバクテリウムビフィダム菌株及び菌株由来多糖体
AU2019358875B2 (en) Combination therapy for treatment and prevention of autoimmune and inflammatory diseases
Liu et al. Intestinal bacteria encapsulated by biomaterials enhance immunotherapy
CA3212817A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
Hume et al. The pathogenesis of Crohn's disease in the 21st century
EP3758723A1 (en) Methods for prognosing and treating metabolic diseases
Rahman et al. Fecal microbiota transplantation in pigs: current status and future perspective
Florio et al. Discovering the Nutrition-Microbiota Interplay in Inflammatory Bowel Disease: Are We There Yet?
JP2025153503A (ja) 糞便細菌叢を含む医薬組成物
Aguilera Microbiota Signals during the Neonatal Period Forge Life-Long Immune Responses
Raftery et al. Links Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease. Front. Immunol. 11: 2144. doi: 10.3389/fimmu. 2020.02144 Links Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease April L. Raftery
Ababio et al. Inflammatory bowel disease: pathogenetic mechanisms

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)